ACT Genomics Taiwan
Healthcare Services · Taiwan · 201-500 Employees
View Company Info for Free
Overview
Headquarters
3f no.345 Xinhu 2nd Neihu Dist Rd, Taipe...Phone Number
+886 227953660Website
www.actgenomics.comRevenue
$5.5 MillionIndustry
ZI Rank: 3
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
1
3
2
3
3
About ACT Genomics Taiwan
ACT Genomics is a cancer solution provider. They offer precision medicine services in Taiwan, Singapore, Hong Kong, and Japan. They combine experts of tumor biology, cancer genomics, and bioinformatics to provide treatment guidelines for solid tumors, relapse, drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluation.Explore more
ACT Genomics Taiwan Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ACT Genomics Taiwan your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if ACT Genomics Taiwan has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at ACT Genomics Taiwan
Click to see if ACT Genomics Taiwan had a recent Job posting/layoffs
Check out if ACT Genomics Taiwan is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when ACT Genomics Taiwan launches new products
ACT Genomics Taiwan, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once ACT Genomics Taiwan has new funding data
Earning: See what the market has to say on ACT Genomics Taiwan recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at ACT Genomics Taiwan
Find 2 more new buyers
Company Profile Activity
Activity Insights
ACT Genomics Taiwan is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
ACT Genomics Taiwan is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about ACT Genomics Taiwan.
ACT Genomics Taiwan financials insights
Gather financial insights about ACT Genomics Taiwan, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$8M
2016
Series B
$12.5M
ACT Genomics Taiwan Tech Stack
A closer look at the technologies used by ACT Genomics Taiwan
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Hiring Plans
ACT Genomics Taiwan has more open roles in Human Resources than it has had at any time in the past 12 months.
Hiring Plans
Open Position
ACT Genomics Taiwan News & Media
Delta Electronics to acquire majority stake in ACT Genomics for biomedical growth
Delta Electronics revealed on June 18 its intention to acquire shares worth up to US$11.78 million in ACT Genomics Holdings Company Limited, a prominent cancer testing firm in Asia. The goal is to attain over 90% ownership, contingent on fulfilling contractual terms and obtaining regulatory approval.Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology
LONDON and HONG KONG, March 2, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Advisory Board (the 'SAB') to provide strategic input based on their scientific knowledge and clinical expertise to help guide the further development of Prenetics' diagnostic cancer genomics platform. Prenetics has been at the forefront of genomic and diagnostic testing, providing a wide rangePrenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology market FDA market authorization advances personalized cancer care in Asia Clearance sets the stage for continued R&D investment into early detection / liquid biopsy LONDON and HONG KONG, Jan. 10, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced that ACT Genomics, a company whichPrenetics Acquires ACT Genomics
Prenetics Global Limited (NASDAQ: PRE), a Hong Kong-based genomic and diagnostic testing company, is to acquire ACT Genomics, an Asia-based genomics company specializing in precision oncology. The amount of the deal consisted of 19.9 million shares of Prenetics common stock and US$20 million cash. With the acquisition, Prenetics will expand its footprint in the cancer […] The post Prenetics Acquires ACT Genomics appeared first on FinSMEs.
Read more news
Top Healthcare Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ACT Genomics Taiwan
Sign Up For FreeTo access detailed company insights
ACT Genomics is a cancer solution provider. They offer precision medicine services in Taiwan, Singapore, Hong Kong, and Japan. They combine experts of tumor biology, cancer genomics, and bioinformatics to provide treatment guidelines for solid tumors, relapse, drug resistance, as well as cancer monitoring, risk assessment, and immunotherapy evaluat... Read More
